YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.

PubWeight™: 1.53‹?› | Rank: Top 4%

🔗 View Article (PMID 17020973)

Published in Clin Cancer Res on October 01, 2006

Authors

Adília Hormigo1, Bin Gu, Sasan Karimi, Elyn Riedel, Katherine S Panageas, Mark A Edgar, Meena K Tanwar, Jasti S Rao, Martin Fleisher, Lisa M DeAngelis, Eric C Holland

Author Affiliations

1: Clinical Laboratories, Neurosurgical Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. hormigoa@mskcc.org

Articles citing this

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01

YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene (2009) 1.97

Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem (2011) 1.50

Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol (2009) 1.46

Recent advances in the molecular understanding of glioblastoma. J Neurooncol (2012) 1.29

A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma. PLoS One (2014) 1.26

YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol (2008) 1.23

Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol (2009) 1.20

In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation (2010) 1.20

Secretome signature of invasive glioblastoma multiforme. J Proteome Res (2011) 1.13

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol (2011) 1.00

Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol (2011) 0.99

The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice. Int J Cancer (2009) 0.99

YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer (2009) 0.97

Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLoS One (2012) 0.93

Resveratrol represses YKL-40 expression in human glioma U87 cells. BMC Cancer (2010) 0.88

An Eighteen Serum Cytokine Signature for Discriminating Glioma from Normal Healthy Individuals. PLoS One (2015) 0.87

Chitinase-3-like-1/YKL-40 as marker of circulating tumor cells. Transl Lung Cancer Res (2015) 0.85

Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma. Carcinogenesis (2013) 0.85

Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. Neuro Oncol (2012) 0.84

Blood-based biomarkers for malignant gliomas. J Neurooncol (2013) 0.84

Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells. Mol Cell Proteomics (2014) 0.84

Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization. Oncotarget (2015) 0.83

YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) (2010) 0.83

Liquid biopsies in patients with diffuse glioma. Acta Neuropathol (2015) 0.82

Circulating glioma biomarkers. Neuro Oncol (2014) 0.80

Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40. J Histochem Cytochem (2014) 0.80

Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. J Neurooncol (2012) 0.80

Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS). J Neural Transm (Vienna) (2013) 0.78

High CHI3L1 expression is associated with glioma patient survival. Diagn Pathol (2016) 0.77

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma. Front Oncol (2014) 0.76

Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma. J Neurooncol (2016) 0.75

Cerebrospinal Fluid Biomarkers of Simian Immunodeficiency Virus Encephalitis : CSF Biomarkers of SIV Encephalitis. J Neuroimmune Pharmacol (2016) 0.75

The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of patients with brain tumor. Arch Med Sci (2017) 0.75

Transcriptome sequencing of neurologic diseases associated genes in HHV-6A infected human astrocyte. Oncotarget (2016) 0.75

PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma. Int J Mol Sci (2016) 0.75

Evaluation of matrix metalloproteinase type IV-collagenases in serum of patients with tumors of the central nervous system. J Neurooncol (2016) 0.75

Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma. PLoS One (2016) 0.75

Immunophenotypic signature of primary glioblastoma multiforme: A case of extended progression free survival. World J Clin Cases (2017) 0.75

Articles by these authors

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45

Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36

CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04

Glioblastoma and other malignant gliomas: a clinical review. JAMA (2013) 4.99

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell (2009) 4.94

Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature (2008) 4.87

Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med (2006) 4.71

A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med (2012) 4.64

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39

Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37

Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg (2003) 4.25

How to build and interpret a nomogram for cancer prognosis. J Clin Oncol (2008) 4.24

The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 4.15

Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10

The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med (2003) 4.01

Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell (2003) 3.68

Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61

Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53

PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50

KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol (2005) 3.47

Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45

Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 3.34

Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27

Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03

Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol (2006) 2.99

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89

Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA (2003) 2.85

Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg (2002) 2.71

Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann Surg Oncol (2003) 2.69

Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res (2006) 2.68

Clinicopathological features of and risk factors for multiple primary melanomas. JAMA (2005) 2.62

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 2.62

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood (2011) 2.59

ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev (2009) 2.59

Developing a cancer-specific geriatric assessment: a feasibility study. Cancer (2005) 2.57

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51

Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A (2006) 2.51

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol (2006) 2.51

Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell (2012) 2.50

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46

Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res (2002) 2.45

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44

Brain metastases. Neurol Clin (2003) 2.44

Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology (2004) 2.41

RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem (2005) 2.38

Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res (2004) 2.36

Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med (2003) 2.33

Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol (2006) 2.32

Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res (2003) 2.32

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31

Incremental Support Vector Learning for Ordinal Regression. IEEE Trans Neural Netw Learn Syst (2014) 2.25

A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol (2012) 2.24

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23

Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial. J Clin Oncol (2002) 2.20

Patterns of care in elderly glioblastoma patients. Ann Neurol (2008) 2.17

Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res (2011) 2.17

TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14

The brain tumor microenvironment. Glia (2011) 2.13

Association between incident cancer and subsequent stroke. Ann Neurol (2015) 2.13

Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem (2004) 2.07

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07

mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04

Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res (2006) 2.01

Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst (2006) 2.01

(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01

Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science (2008) 1.99

Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci (2003) 1.99

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol (2006) 1.98

Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res (2010) 1.97

Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene (2004) 1.96

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94

Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol (2012) 1.93

Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology (2005) 1.91

Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene (2004) 1.91

Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res (2005) 1.91

Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol (2009) 1.89

A Robust Regularization Path Algorithm for $\nu $ -Support Vector Classification. IEEE Trans Neural Netw Learn Syst (2016) 1.86

Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest (2005) 1.85

The use of acellular dermal matrices in two-stage expander/implant reconstruction: a multicenter, blinded, randomized controlled trial. Plast Reconstr Surg (2012) 1.84

PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 1.82

Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res (2002) 1.82

Cancer screening among patients with advanced cancer. JAMA (2010) 1.82